LY 3200882 is primarily investigated for its potential therapeutic applications in the treatment of Alzheimer's disease. It functions as a selective inhibitor of the enzyme beta-secretase 1 (BACE1), which plays a critical role in the production of amyloid-beta peptides. These peptides are known to accumulate in the brains of Alzheimer's patients, forming plaques that disrupt neural function. By inhibiting BACE1, LY 3200882 aims to reduce the formation of amyloid-beta plaques, potentially slowing the progression of the disease.

In preclinical studies, LY 3200882 has demonstrated promising results in lowering amyloid-beta levels in animal models, suggesting its potential efficacy in humans. Researchers are particularly interested in its ability to cross the blood-brain barrier, a crucial factor for drugs targeting central nervous system disorders.

Additionally, LY 3200882 is being explored for its application in other neurodegenerative conditions where amyloid-beta accumulation is implicated, such as mild cognitive impairment and certain forms of dementia. Its development represents a significant step forward in the search for disease-modifying treatments for Alzheimer's and related disorders.